The Jerusalem PostJewish ex-Harvard admin. files discrimination suit over termination after Rosh Hashanah leaveBollywood HungamaEmraan Hashmi narrowly escapes injury after car flip stunt goes wrong on Gunmaaster G9 set; watchESPN DeportesBills salta al Top 3 y Chiefs se mantienen en la cimaESPNAll 30 NBA teams reveal court designs for 2026 NBA Cup tournamentRTP DesportoStopira despede-se da seleção de Cabo Verde ao fim de 18 anosDaily MaverickWatch — Ekurhuleni murders: What we know about the killings of 12 womenThe Hollywood ReporterReese Witherspoon’s Hello Sunshine Breaks Away From Candle MediaZDF heuteEntdecken Sie das ZDF-NachrichtenstudioBusiness AMMerz wil pensioen- en zorgstelsels hervormen om vertrouwen van jongeren te herstellenCollider14 Years Later, Netflix's Emotional 5-Part Thriller Remains a Perfect Weekend BingeSouth China Morning PostSix Flags closes some rides after man flung to his death from roller coasterSportstarArchery Premier League 2026: Rajputana Royals outplays Chero Archers to make it two wins a row
The Daily Newsstand · Free, Always
Tuesday, October 13, 2026

BPOM partners with 187 universities to boost ATMP ecosystem

Translate

Jakarta (ANTARA) - The Indonesian Food and Drug Authority (BPOM) has partnered with 187 top domestic universities to boost the advanced therapy medicinal products (ATMP) ecosystem through research, innovation, and commercialization.

BPOM head Taruna Ikrar highlighted the move in Jakarta on Tuesday during the signing of a joint commitment with several institutions, including the Ministry of Health and the Ministry of Higher Education, Science, and Technology, to develop the country's stem cell therapy ecosystem.

Ikrar explained that Indonesia has so far authorized only one type of ATMP, which is still imported. By comparison, the US Food and Drug Administration (FDA) has approved 48 ATMP products, while Japan has authorized around 26.

He added that the global market potential for ATMPs reached US$50 billion in 2025 and is projected to grow by 14.15 percent annually.

"As a result, it is predicted to triple or quadruple in the near future—a 200 percent increase from current levels," he said.

To address this, the agency is actively supporting research by offering guidance on preclinical trials, in addition to working closely with key stakeholders.

He explained that one of the innovative products currently undergoing trials aims to treat osteoarthritis, a condition affecting many Indonesians.

On the same occasion, Director General of Research and Development at the Ministry of Higher Education, Science, and Technology, Mohammad Fauzan Adziman, said that through its Hilirisasi initiative, the ministry aims to advance innovations toward commercialization.

Part of these efforts includes collaboration with BPOM, he noted, adding that around 4,000 healthcare research projects across Indonesia are being funded in 2026.

He expressed hope that such initiatives will support lecturers to conduct meaningful research backed by scientific evidence that leads to commercially viable products.

Related news: Drug, food industry could add Rp10,000 trillion yearly: BPOM

Related news: Indonesia, China set to sign new deal on drug and food safety

Related news: BPOM invites pharmaceutical industry to bolster clinical trials

Translator: Mecca Yumna, Raka Adji
Editor: Azis Kurmala
Copyright © ANTARA 2026

View the original on Antara News →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.